

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lung cancer	Deoxythymidylate kinase (DTYMK); serine/threonine kinase 11 (STK11; LKB1)	Cell culture studies suggest inhibiting DTYMK could help treat <i>LKB1</i> mutant lung cancer. A small hairpin RNA screen in mouse cells derived from lung tumors showed that <i>Dtymk</i> deficiency was lethal in <i>Lkb1</i> mutant cells. In a panel of <i>LKB1</i> mutant lung cancer cell lines, <i>DTYMK</i> -targeting shRNA decreased growth compared with control shRNA. Next steps could include developing pharmacological inhibitors of DTYMK.	Patent and licensing status unavailable	Liu, Y. <i>et al. Cancer Discov.</i> ; published online May 28, 2013; doi:10.1158/2159-8290.CD-13-0015 Contact: Kwok-Kin Wong, Dana-Farber Cancer Institute, Boston, Mass. e-mail: kwong1@partners.org
<p><i>SciBX</i> 6(26); doi:10.1038/scibx.2013.653 Published online July 11, 2013</p>				